Jim Cramer: Stay in Eli Lilly Stock Despite High Price

Jim Cramer, the well-known host of CNBC's Mad Money, advised investors to hold shares of Eli Lilly and Company (NYSE:LLY) despite its high share price. The comment came during an episode where Cramer highlighted notable players in the healthcare space and reviewed several of this year's IPOs.

Details of the Call

When a caller expressed concern about the high share price and speculated that the company might split the stock, Cramer responded: "I don't know if they're going to split the stock... but I want you to stay in the stock." He did not provide further details on the likelihood of a stock split.

Context

Cramer's recommendation comes amid strong performance for Eli Lilly, driven by robust sales of its blockbuster drugs Mounjaro (for diabetes) and Zepbound (for obesity). The stock has risen over 50% in the past year, making it one of the highest-priced stocks in the market.

What It Means for Investors

Cramer's advice reflects confidence in Eli Lilly's growth prospects, particularly given the sustained demand for its key products. However, investors should weigh the risks associated with the stock's high valuation and potential price corrections.